Pharma

Politics Bob Herman

STAT Plus: Biden administration axes proposal to mandate more drug price transparency in Medicaid

The Readout Elaine Chen

STAT Plus: Biotech’s real estate market is still upside down

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more

Pharmalot Ed Silverman

STAT Plus: Moderna is scolded by a U.K. trade group for offering kids $2,000 to participate in a Covid trial

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Generic drug lobby taps former BIO exec as new CEO

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Sanders and Novo Nordisk CEO sparring, Roche refocusing, and more

The Readout Elaine Chen

STAT Plus: The science behind Summit’s success, 23andMe’s fate, and more biotech news updates

Pharmalot Ed Silverman

STAT Plus: Baltimore claims Biogen ‘bribed’ PBMs to favor its pricey MS drug over generics

Health tech Mohana Ravindranath

STAT Plus: Can AI reduce health care fraud, AI firm in Texas AG’s crosshairs, and more

Politics Rachel Cohrs Zhang and Elaine Chen

STAT Plus: Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Regeneron biosimilar fight, a ‘positive surprise’ for Biogen lupus drug, and more

The Readout Elaine Chen

STAT Plus: Metsera’s GLP-1 drug has potential for monthly dosing, new data show

Politics Leslie Walker and Dan Gorenstein

STAT Plus: The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to start the week

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a ‘Bust Big Pharma’ bus tour, few smoking-cessation drugs, and more

Health Nicholas Florko

Millions of Americans want to quit smoking. Critics say drugmakers and the FDA are failing them

Exclusive Rachel Cohrs Zhang

STAT Plus: A mysterious anti ‘Big Pharma’ bus is barnstorming swing states

Politics John Wilkerson

STAT Plus: Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say

Pharma Rachel Cohrs Zhang

STAT Plus: PhRMA scores a small win in legal challenge to Medicare’s drug price negotiation

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharma Jason Mast

STAT Plus: FDA approves first drug for rare neuron disease, Niemann-Pick type C

Pharmalot Ed Silverman

STAT Plus: FTC sues big 3 PBMs for ‘artificially inflated’ insulin prices caused by ‘perverse’ rebating

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about weight loss drug prices, correcting patent mistakes, and more

The Readout Meghana Keshavan

STAT Plus: Are generalist investors good or bad for biotech?

Exclusive John Wilkerson

STAT Plus: Cassidy seeks to exempt small biotechs from Medicare drug price negotiation 

Pharmalot Ed Silverman

STAT Plus: FDA cites Granules, a large Indian generic drug manufacturer, for tossing truckloads of key documents

Pharmalot Ed Silverman

STAT Plus: Lawmakers urge U.S. Patent Office and drugmakers to correct patent mistakes

The Readout Elaine Chen

STAT Plus: The Fed cut rates and biotech stocks… didn’t do much

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a rare-disease drug bill, compounded Wegovy, and more